Of these cases, approximately 15–25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes. However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings.
Includes the most up-to-date treatment and diagnostic guidelines, include American Society of Clinical Onocology (ASCO) and National Comprehensive Cancer Network (NCCN)
In-depth discussion of the recent breakthrough drug developments that have revolutionized breast cancer treatment over the past decade
Concise scope and size is specifically tailored to meet the demands of busy clinical professionals and trainees.